The Wellstone group has submitted a paper describing analyses of DUX4 expression in cells and tissues from FSHD patients and their relatives. Authors from our group include Jeff, Sachiko Homma, and Mary Lou Beerman. Our BBRI colleague, Peter Jones, is the senior author of this manuscript.
We’ve started work on the CMD and LGMD studies supported by a new award from the Muscular Dystrophy Association (details).
Our entire lab group participated in the FSHD International Consortium Meeting. Our Wellstone Center was well represented with five platform talks and an additional four posters.
The European Journal of Human Genetics has accepted and will soon publish our paper on the use of FSHD and normal myogenic cells to probe effects of disease and family origin on differentiation and gene expression. (Abstract from PubMed)
We’ve submitted an abstract and Jeff will give a platform talk on the effects of FSHD disease and family origin on differentiation and gene expression in myogenic cells at the FSHD International Consortium Meeting.
Our Wellstone group has submitted a paper on the use of FSHD and normal myogenic cells to probe effects of disease and family origin on differentiation and gene expression.
Our paper on peripheral nerve pathology in laminin-alpha2-deficiency has been published by Human Molecular Genetics (Abstract from PubMed).
In Tucson, Jeff took part in the spring meeting of the Scientific Advisory Committee of the Muscular Dystrophy Association.
We held our third annual Wellstone Center retreat at BBRI, with presentations from all groups.
Drs. Sachiko Homma and Jim Windelborn attended the MDA Conference in Las Vegas. Sachiko presented her work on peripheral neuropathy.
Dr. Sachiko Homma, Mary Lou Beermann and Jeff have submitted an abstract to the MDA Conference describing our work on peripheral nerve pathology in laminin-alpha2-deficiency.
Dr. James Windelborn has joined our group from the University of Wisconsin.
Our Wellstone group participated in the annual meeting of the FSH International Research Consortium at BBRI.
In Tucson, Jeff took part in the fall meeting of the Scientific Advisory Committee of the Muscular Dystrophy Association.
In response to recent events, BBRI has issued a statement that unreservedly endorses NIH funding of human embryonic stem cell research. Read the BBRI policy statement.
The Wellstone FSHD Center held its second annual retreat with presentations by all center investigators including an update by our group on our mitochondrial and oxidative stress studies.
Our group contributed to a paper presented by the Wellstone Center at the Ottawa Conference on New Directions in Biology & Diseases of Skeletal Muscle.
Our paper on the role of Prdm1 in muscle development and fiber type diversification has been published by PLoS One. (read it)
The BBRI-based Wellstone Center for FSHD Research had five presentations, including one by Jeff, at the annual FSHD International Research Consortium and Planning meeting sponsored by The FSH Society.
Jeff presented a seminar on our work at the Pioneer Valley Life Science Institute.
Our paper identifying Ku70 as a regulator of Bax-mediated pathogenesis in models of congenital muscular dystrophy has been published in Human Molecular Genetics. (read Abstract on PubMed; Request reprint)
Jeff spoke at the conference on “Therapeutic Targets in the Congenital Muscular Dystrophies” organized by the CureCMD Foundation. An international group of ~100 attendees included researchers, clinicians, patient advocates, industry representatives, and NIH staff. (see agenda)
Our first annual Wellstone FSHD Center retreat was held at BBRI. Presenters included Center PIs (Kathryn Wagner, Louis M. Kunkel, Charles P. Emerson, Robert J. Bloch, Jeff Miller, Woody Wright, Mayana Zatz), postdoctoral fellows, members of our Scientific Advisory Board, invited speakers, and representatives of patient groups including our Wellstone Center partner The FSH Society and also the FSHD Global Research Foundation. (read the press release)